Physician profile

John Y Hess

Cardiovascular Disease · Thousand Oaks, CA

NPI 1053504910

$1,707.92

in general payments reported to CMS, 2019-2025

19 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $368.12 2019-2020
Abbott Laboratories $364.98 2019-2022
Novartis Pharmaceuticals Corporation $233.55 2019-2020
Amarin Pharma, INC. $130.46 2019-2020
Medtronic Vascular, INC. $127.35 2019-2020
Edwards Lifesciences Corporation $99.85 2019
E.R. Squibb & Sons, L.L.C. $94.97 2019-2020
Astrazeneca Pharmaceuticals LP $47.55 2019
Boehringer Ingelheim Pharmaceuticals, INC. $39.44 2019
Gilead Sciences, INC. $33.46 2019
Janssen Pharmaceuticals, INC $31.30 2020
Sanofi-Aventis U.S. LLC $24.65 2019
Boston Scientific Corporation $24.06 2020
Arbor Pharmaceuticals, INC. $18.91 2019
Kowa Pharmaceuticals America, INC. $18.12 2019
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Angiodynamics, INC. $16.68 2020
Actelion Pharmaceuticals US, INC. $14.76 2019
Tactile Systems Technology INC $14.14 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $5.57 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Y Hess

$1,707.92

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/2406/john-y-hess

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.